Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARI-3037MO in Patients With Dysglycemia and NAFLD/NASH
NCT02574325Phase 2Unknown
- Sponsor
- Arisaph Pharmaceuticals
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH) comparing ARI-3037MO with Placebo (2 arms). Primary endpoints: Change in Intrahepatic Fat Content at 24 weeks, Change in Plasma ALT Levels at 24 weeks and 1 more. Status: unknown.
02
Drugs
ARI-3037MO
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02574325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574325.